Ipamorelin (10 mg Vial) Dosage Protocol

Plan based on an 8–16 week daily protocol with gradual titration.

• Peptide Vials (Ipamorelin, 10 mg each):
  • 8 weeks: approximately 2 vials required
  • 12 weeks ≈ 2–3 vials
  • 16 weeks: approximately 3 vials required
• Insulin Syringes (U-100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (2 vials): 6 mL — 1 bottle required (10 mL each)
  • 12 weeks (2–3 vials): 6–9 mL — 1 bottle required (10 mL each)
  • 16 weeks (3 vials): 9 mL — 1 bottle required (10 mL each)
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs — 2 boxes required (100 swabs each)
  • 12 weeks: 168 swabs — 2 boxes required (100 swabs each)
  • 16 weeks: 224 swabs — 3 boxes required (100 swabs each)

Ipamorelin 10 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
• Typical daily range: 100–300 mcg once daily (gradual titration recommended).
• Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33 mcg on a U-100 insulin syringe.
• Storage: Lyophilized: 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and follow the exact formulation’s validated use-by period.

Ipamorelin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue by mimicking ghrelin at the GH secretagogue receptor^[1][2]. Its key advantage is high specificity for GH release without triggering ACTH or cortisol elevation, making it one of the safer GH secretagogues with minimal off-target hormonal effects^[1][3]. This educational protocol presents a once-daily subcutaneous approach using practical dilution for precise insulin-syringe measurements.

This ipamorelin dosage guide connects the existing calculation chart above with the published evidence behind ipamorelin. The chart keeps the 10 mg vial, 3.0 mL final volume, syringe-unit conversions, timing, and staged rows already established on this page. Those rows are an educational calculation framework. They are not an approved clinical regimen and should not be presented as though they were tested in the human trials summarized below.

• Compound: Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue that binds the growth hormone secretagogue receptor, also called GHSR-1a.^[1][2]
• 10 mg vial math: The page uses 3.0 mL of bacteriostatic water, producing approximately 3.33 mg/mL. On a U-100 insulin syringe, 1 unit is 0.01 mL and contains approximately 33 mcg at that concentration.
• Evidence boundary: Human ipamorelin research used intravenous administration, including controlled infusion pharmacology and a postoperative-ileus trial. Those studies did not validate this page’s subcutaneous schedule.^[2][3][4]
• Regulatory context: Ipamorelin is not an FDA-approved drug. FDA materials identify safety and quality concerns for compounded ipamorelin acetate, particularly for proposed subcutaneous administration.^[11][12]
• Sport context: The 2026 World Anti-Doping Agency Prohibited List names ipamorelin among growth hormone secretagogues prohibited at all times.^[13]

The primary ipamorelin dosage chart keeps mass, U-100 units, injection volume, frequency, and duration together so each row can be interpreted without a second table. The vial strength determines how much peptide is available, while the 3.0 mL final volume determines the concentration. The vial strength does not independently establish an ipamorelin dose or research cycle.

For this 10 mg vial, the concentration calculation is 10 mg divided by 3.0 mL, or approximately 3.33 mg/mL. One U-100 unit equals 0.01 mL, so each unit represents approximately 0.0333 mg, or 33 mcg. The displayed unit values are rounded syringe markings. They are volume measurements, not international units of peptide activity.

The page’s existing rows remain unchanged. Any researcher checking the math should confirm the vial label, final liquid volume, concentration, intended mass, and resulting mL before using an insulin syringe. The site’s peptide dosage calculator can independently check arithmetic, but it does not select a dose, timing and frequency, cycle length, or route.

The clearest human pharmacology study enrolled eight healthy men and evaluated five intravenous infusion dose levels. Investigators reported dose-proportional pharmacokinetics, an estimated terminal half-life of about two hours, and a growth hormone peak at approximately 0.67 hours. Because the compound was delivered by intravenous infusion, the study does not establish a subcutaneous ipamorelin dosage, bedtime protocol, or 10 mg vial schedule.^[2]

A later randomized, placebo-controlled phase 2 trial studied intravenous ipamorelin after bowel resection. The published report used 0.03 mg/kg twice daily for up to seven days and did not find a statistically significant difference in the primary efficacy endpoint. The registered study also documents additional intravenous arms. This was a postoperative gastrointestinal-motility investigation, not a body-composition, sleep quality, fat loss, lean muscle, or performance trial.^[3][4]

Preclinical experiments help explain why ipamorelin was developed as a selective growth hormone secretagogue. Early animal work compared its growth hormone release profile with other secretagogues, while rodent studies examined gastric emptying, postoperative ileus, chronic exposure, and body-weight effects.^{[1][5][6][7][8][9]} Animal findings can support a mechanism hypothesis, but they cannot determine a human ipamorelin peptide dosage or prove the outcomes advertised in commercial peptide therapy material.

Recent sports-medicine reviews describe the expanding use of performance-enhancing peptides and emphasize evidence gaps, product-quality uncertainty, and anti-doping consequences. They are useful for risk context, but they do not turn a community schedule into an approved dosing protocol.^[14][15]

Ipamorelin activates the growth hormone secretagogue receptor rather than acting as synthetic growth hormone. GHSR-1a is a ghrelin receptor expressed in the pituitary and other tissues. Receptor activation can stimulate a pulse of growth hormone from the pituitary gland. Foundational animal experiments characterized ipamorelin as the first selective growth hormone secretagogue because it released growth hormone with less ACTH and cortisol activity than comparator compounds in those models.^[1]

Growth hormone-releasing hormone, often abbreviated GHRH, and ghrelin-receptor agonists act through different receptors and signaling pathways. Their effects can interact at the pituitary, but a GHRH analog and ipamorelin are not interchangeable compounds. Claims that ipamorelin automatically improves muscle growth, body composition, recovery, sleep quality, or fat loss require outcome-specific human evidence. A transient GH pulse or increased growth hormone release is a pharmacodynamic signal, not proof of a long-term clinical benefit.^[2][10]

The human infusion study measured short-term growth hormone stimulation. It did not establish that repeated subcutaneous injections produce a specific change in lean muscle growth, insulin-like growth factor levels, or athletic recovery. This distinction is central to interpreting any ipamorelin dosage guide accurately.

This page covers standalone ipamorelin from a 10 mg vial. It does not provide a CJC-1295 ipamorelin dosage. CJC-1295 and ipamorelin are different peptides that act through different receptor systems, so a blend calculation cannot be copied into a standalone ipamorelin protocol.

CJC-1295 is discussed in more than one form online, including CJC-1295 with DAC and CJC-1295 without DAC. Those formulations have different pharmacokinetic considerations. CJC-1295 dosing, CJC-1295 and ipamorelin dosing, and an ipamorelin dose from a single-compound vial therefore require separate concentration math and separate evidence review. A page about using CJC-1295 ipamorelin together should also specify whether the products are premixed or supplied in separate vials.

Readers comparing CJC-1295 and ipamorelin can use the related-protocol links below, but the comparison does not establish that an ipamorelin combination is superior or appropriate. The dosage chart on this page remains specific to the labeled 10 mg ipamorelin vial and its existing calculation schedule.

Published human exposure is limited, and the available studies do not provide a long-term safety database for repeated subcutaneous use. The postoperative trial reported adverse-event data in a monitored clinical setting, but its intravenous route, surgical population, and short treatment window limit generalization to community ipamorelin dosage protocols.^[3]

FDA’s current compounding-safety material states that ipamorelin acetate may present risks related to immunogenicity and peptide impurities. It also notes insufficient safety information for the proposed subcutaneous route. The agency’s 2024 briefing document reviews nonclinical findings, published human studies, dosing information submitted for consideration, and the absence of an approved drug product containing ipamorelin.^[11][12]

Side effects described in commercial or community material should not be treated as a complete incidence table. Product identity, purity, aggregation, sterility, and endotoxin burden can change risk independently of the nominal ipamorelin dose. Recent medical reviews similarly caution that performance-enhancing peptide use often runs ahead of controlled evidence.^[14][15]

For sport, the anti-doping issue is separate from clinical safety. WADA classifies ipamorelin as a prohibited growth hormone secretagogue. Athletes are responsible for checking the current rules and any medication or supplement exposure before competition.^[13]

Peptide stability depends on the exact formulation, container, temperature, light exposure, moisture, reconstitution liquid, and sterility controls. The four reconstitution checks in the chart above preserve this page’s established process: add 3.0 mL of bacteriostatic water, direct the liquid slowly down the vial wall, swirl or roll gently without vigorous shaking, then label and refrigerate at 2–8 °C while protecting the vial from light.

General peptide-handling guidance supports minimizing repeated temperature cycling, moisture exposure, contamination, and unnecessary agitation.^[16] A universal discard period should not be inferred from the 10 mg strength alone. Follow the labeled product and lot documentation for a validated storage or discard interval. The Pure Lab Peptides product page is included for bottle identification and provenance, not as scientific evidence for an ipamorelin dosage.^[20]

The chart specifies a subcutaneous route. General injection resources recommend clean hands and a clean work surface, a new sterile syringe for each injection, an alcohol-cleaned vial stopper and skin site, systematic site rotation, and immediate disposal in an approved sharps container.^[17][18][19]

• Confirm that the vial contains 10 mg and that the final liquid volume is 3.0 mL before using the page’s unit conversions.
• Read the U-100 insulin syringe at eye level. A unit is a volume marking equal to 0.01 mL, not a biological measure of ipamorelin activity.
• Remove visible air bubbles before checking the final volume against the row in the ipamorelin dosage chart.
• Rotate sites and avoid areas that are bruised, scarred, inflamed, or otherwise unsuitable for subcutaneous injection.^[17][19]
• Do not reuse needles or syringes, and do not place loose sharps in household recycling.^[18]

These technique points describe handling and measurement. They do not validate the schedule, select an ipamorelin dose, or replace product-specific laboratory procedures.

What concentration does a 10 mg ipamorelin vial make with 3.0 mL?

Ten milligrams divided by 3.0 mL equals approximately 3.33 mg/mL. At this concentration, 0.01 mL, or one U-100 syringe unit, contains approximately 33 mcg. This is calculation information, not a dose recommendation.

Does a larger ipamorelin vial change the research schedule?

No. Vial strength changes the total amount available and may change concentration or vial yield. It does not by itself determine the dose, route, timing and frequency, or cycle length. Each strength-specific page must keep its own calculation checks while the compound-level evidence remains consistent.

What ipamorelin dosage was studied in humans?

Human studies used intravenous administration. One pharmacology study tested five intravenous infusion levels in eight healthy men, while a phase 2 postoperative-ileus trial used weight-based intravenous dosing. Neither study validated the subcutaneous calculation schedule on this page.^[2][3]

Is ipamorelin an approved medication?

No FDA-approved drug product contains ipamorelin. FDA has published safety concerns about compounded ipamorelin acetate and found insufficient evidence for the proposed subcutaneous uses reviewed in its materials.^[11][12]

Is an ipamorelin protocol the same as a CJC-1295 and ipamorelin protocol?

No. The compounds use different receptor pathways, and CJC-1295 with DAC differs from CJC-1295 without DAC. A CJC-1295 and ipamorelin dosage protocol requires its own vial composition, concentration, and evidence review. This page is limited to standalone ipamorelin.

What does one unit mean on this ipamorelin dosage chart?

On a U-100 insulin syringe, one unit is 0.01 mL of liquid. With the page’s 3.33 mg/mL concentration, that volume contains approximately 33 mcg of ipamorelin. U-100 units are volume markings and should not be confused with peptide IU.

How should reconstituted ipamorelin be stored?

The chart instructs refrigeration at 2–8 °C with protection from light. Stability and discard timing are formulation-specific, so the vial label and lot documentation remain the controlling sources for a validated use-by period.^[16]

Is ipamorelin prohibited in sport?

Yes. The WADA 2026 Prohibited List includes ipamorelin among growth hormone secretagogues prohibited at all times.^[13]

This page separates vial calculations from evidence claims. The displayed schedule is an educational calculation framework and is not an approved standard of care, a treatment recommendation, or proof of safety or efficacy.

• 1
  European Journal of Endocrinology (PubMed): Ipamorelin, the first selective growth hormone secretagogue (1998 preclinical pharmacology study)

  View Source
• 2
  Pharmaceutical Research (PubMed): Pharmacokinetic-pharmacodynamic modeling of ipamorelin in healthy volunteers (1999 human infusion study)

  View Source
• 3
  International Journal of Colorectal Disease (PubMed): Randomized proof-of-concept study of intravenous ipamorelin after bowel resection (2014 phase 2 trial)

  View Source
• 4
  ClinicalTrials.gov: NCT01280344: intravenous ipamorelin for postoperative ileus

  View Source
• 5
  Neurogastroenterology & Motility (PubMed): Ipamorelin and gastric emptying in an animal model

  View Source
• 6
  Experimental animal research (PubMed): Ipamorelin in a rodent postoperative-ileus model

  View Source
• 7
  Endocrine research (PubMed): Chronic ipamorelin exposure and growth-related outcomes in rats

  View Source
• 8
  Growth-hormone research (PubMed): Repeated ipamorelin exposure and growth-hormone responses in rats

  View Source
• 9
  Preclinical motility research (PubMed): Ghrelin-receptor agonism and gastrointestinal-motility endpoints

  View Source
• 10
  Translational Andrology and Urology (PMC): Review of growth hormone secretagogues and the limits of body-composition evidence

  View Source
• 11
  U.S. Food and Drug Administration: Safety risks associated with certain bulk drug substances used in compounding

  View Source
• 12
  U.S. Food and Drug Administration: 2024 Pharmacy Compounding Advisory Committee briefing document for ipamorelin

  View Source
• 13
  World Anti-Doping Agency: 2026 Prohibited List, growth hormone secretagogues including ipamorelin

  View Source
• 14
  Sports medicine review (PubMed): Performance-enhancing peptides: evidence, risk, and regulatory considerations (2026)

  View Source
• 15
  Clinical sports medicine review (PubMed): Peptide use in sport and limitations of current evidence (2026)

  View Source
• 16
  NIBSC: Peptide handling, dissolution, and storage guidance

  View Source
• 17
  Johns Hopkins Arthritis Center: How to give a subcutaneous injection

  View Source
• 18
  NCBI Bookshelf: Best practices for injection preparation, asepsis, administration, and sharps disposal

  View Source
• 19
  Pharmacologic considerations (PMC): Subcutaneous drug injection and site-rotation considerations

  View Source
• 20
  Pure Lab Peptides: Ipamorelin 10 mg bottle identification and product provenance

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.